Intas Pharmaceuticals Limited — Methotrexate Exporter Profile
Indian Pharmaceutical Exporter · #3 for Methotrexate · $1.5M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #3 Indian exporter of Methotrexate with $1.5M in export value and 109 verified shipments. Intas Pharmaceuticals Limited holds a 4.4% market share in Methotrexate exports across 11 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Methotrexate Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Methotrexate?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $901.0K | 32 | 51.6% |
| MEXICO | $578.7K | 17 | 33.1% |
| AUSTRALIA | $122.6K | 6 | 7.0% |
| NETHERLANDS | $50.7K | 19 | 2.9% |
| UNITED KINGDOM | $31.0K | 6 | 1.8% |
| POLAND | $24.4K | 3 | 1.4% |
| SPAIN | $15.5K | 25 | 0.9% |
| FRANCE | $11.3K | 1 | 0.6% |
| PERU | $6.1K | 2 | 0.3% |
| GREECE | $5.8K | 1 | 0.3% |
Intas Pharmaceuticals Limited exports Methotrexate to 11 countries. The largest destination is CANADA accounting for 51.6% of Intas Pharmaceuticals Limited's Methotrexate shipments, followed by MEXICO (33.1%) and AUSTRALIA (7.0%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Methotrexate from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD HEALTHCARE INC | CANADA | $463.4K | 13 |
| ACCORD FARMA S.A. DE C.V. | MEXICO | $311.9K | 10 |
| ACCORD HEALTHCARE INC. | CANADA | $250.5K | 12 |
| ACCORD FARMA S A DE C V | MEXICO | $131.6K | 4 |
| XXCORXXHEAXXHCAXX INXX | CANADA | $120.6K | 3 |
| TO THE ORDER. | MEXICO | $85.1K | 2 |
| TO THE ORDER | SPAIN | $76.4K | 13 |
| ACCORD HEALTHCARE PTY LIMITED | AUSTRALIA | $65.8K | 3 |
| ACCORD HEALTHCARE PTY LTD | AUSTRALIA | $56.8K | 3 |
| ACCORD FARMA S.A.DE C.V | MEXICO | $50.0K | 1 |
Intas Pharmaceuticals Limited supplies Methotrexate to 29 buyers globally. The largest buyer is ACCORD HEALTHCARE INC (CANADA), followed by ACCORD FARMA S.A. DE C.V. (MEXICO) and ACCORD HEALTHCARE INC. (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Methotrexate Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $21.3M worth of Methotrexate through 3,806 shipments from 353 suppliers to 148 countries, serving 879 buyers globally. Intas Pharmaceuticals Limited contributes $1.5M to this total, accounting for 4.4% of India's Methotrexate exports. Intas Pharmaceuticals Limited ships Methotrexate to 11 countries through 29 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Methotrexate Exports?
Intas Pharmaceuticals Limited's average Methotrexate shipment value is $14.0K per consignment, based on 109 shipments totaling $1.5M. The largest destination is CANADA (51.6% of Intas Pharmaceuticals Limited's Methotrexate exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Methotrexate Exporters?
Intas Pharmaceuticals Limited ranks #3 among 353 Indian Methotrexate exporters with a 4.4% market share. The top 3 exporters are CIPLA LIMITED ($10.8M), EUGIA PHARMA SPECIALITIES LIMITED ($2.9M), INTAS PHARMACEUTICALS LIMITED ($1.5M). Intas Pharmaceuticals Limited processed 109 shipments to 11 destination countries.
What Methotrexate Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| METHOTREXATE 50MG/ML, 0.50ML 1PFSAC-CAN | $140.9K | 3 |
| PHARMA. DRUGS & MEDICINE TRAXACORD 2 ML(25MG/ML 2ML) METHOTREXATE INJ. BP25MG/ML(2ML) | $124.6K | 3 |
| PHARMA DRUGS AND MEDI TRAXACORD 2 ML (25MG/ML, 2ML) METHOTREXATE INJECTION BP 25MG/ML(2ML) EACH ML CONTAINS: METHOTREXATNOS | $89.3K | 3 |
| PH.DRU.& MED TRAXACORD 2 ML (25mg/ml, 2ml) METHOTREXATE INJECTION BP 25MG/ML(2ML) EACH ML CONT.METHOTREXATE PH. EUR.25MG | $85.1K | 2 |
| METHOTREXATE 50MG/ML 0.50ML 1PFS(AC-CAN | $70.6K | 2 |
| PHARMA.DRUGS & MEDICINE METHOTREXATE INJECTION BP-25MG/ML-40ML EACH ML CONTS. METHOTREXATE PH.EUR.25MG WATER FOR INJ. | $61.9K | 2 |
| PHARMA DRUGS & MEDI: METHOTREXATE INJECT | $55.9K | 3 |
| METHOTREXATE 50MG/ML 0.30ML 1PFS(AC-CAN | $50.0K | 1 |
| METHOTREXATE 50MG/ML, 0.35ML 1PFSAC-CAN | $50.0K | 1 |
| METHOTREXATE 50MG/ML, 0.45ML 1PFSAC-CAN | $50.0K | 1 |
Intas Pharmaceuticals Limited exports 91 distinct Methotrexate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is METHOTREXATE 50MG/ML, 0.50ML 1PFSAC-CAN with 3 shipments worth $140.9K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Methotrexate to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Methotrexate to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Methotrexate Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED | $10.8M | 217 | 13 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $2.9M | 58 | 3 | $50.0K |
| 3 | INTAS PHARMACEUTICALS LIMITED ★ | $1.5M | 109 | 11 | $14.0K |
| 6 | NAPROD LIFE SCIENCES PRIVATE LIMITED | $1.2M | 45 | 8 | $25.6K |
| 4 | ZYDUS LIFESCIENCES LIMITED | $950.0K | 19 | 2 | $50.0K |
Intas Pharmaceuticals Limited ranks #3 among 353 Indian Methotrexate exporters. Average shipment value of $14.0K compared to the market average of $60.3K. The closest competitors by value are CIPLA LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Methotrexate Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 890 | 23.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 719 | 18.9% |
| DELHI AIR CARGO ACC (INDEL4) | 415 | 10.9% |
| DELHI AIR | 267 | 7.0% |
| Bombay Air | 239 | 6.3% |
| NHAVA SHEVA SEA (INNSA1) | 148 | 3.9% |
| HYDERABAD AIR | 89 | 2.3% |
| Bombay Air Cargo | 80 | 2.1% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Methotrexate Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Methotrexate, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Methotrexate — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Methotrexate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 118 individual customs records matching Intas Pharmaceuticals Limited exporting Methotrexate, covering 91 formulations to 11 countries via 29 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 148+ countries, 879+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Methotrexate Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Methotrexate exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Methotrexate Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Methotrexate. For current shipment-level data, contact TransData Nexus.